IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

Clinical trial NCT06713837 · RECRUITING

Trial details

NCT number: NCT06713837
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Acute Myeloid Leukemia Relapse/Recurrence

Start date: 2025-02-27
Primary completion: 2028-01-01
Enrollment: 339

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.